Abstract:Background: Type 1 diabetes (T1D) is an autoimmune disorder characterized by the destruction of insulin-producing pancreatic β cells. Understanding the immune mechanisms underlying T1D is crucial for developing effective diagnostic and therapeutic strategies. This study aimed to elucidate the immune mechanisms of T1D by integrating single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, and experimental validation. Methods: scRNA-seq data (GSE200695) and bulk RNA-seq data (GSE9006) were obtained from the Gene Expression Omnibus (GEO) database. After data preprocessing, principal component analysis (PCA), and clustering, cell subtypes were annotated using ImmGenData as a reference. Receptor-ligand interactions were analyzed to identify key cell subtypes. Least absolute shrinkage and selection operator (LASSO) regression was performed to identify characteristic genes and construct a diagnostic model. Key genes were further validated using the training and validation sets. Functional enrichment and immune infiltration analyses were conducted for the key genes. In vitro experiments were performed to validate the findings using a high-glucose model in the monocytic cell line THP-1. siRNA-mediated knockdown of TRIB1 was performed to investigate its role in regulating monocyte activation and immune-related pathways under high-glucose conditions. Monocyte activation markers, inflammatory cytokines, apoptosis, and the expression of key genes and immune-related genes were assessed using immunofluorescence staining, ELISA, flow cytometry, qPCR, and Western blot. Results: Monocytes were identified as the key cell subtype with the most interactions with other cell subtypes. Eleven characteristic genes were selected to construct a diagnostic model, which demonstrated high validation efficiency (AUC > 0.8). Three key genes (ACTG1, REL, and TRIB1) showed consistent expression trends in the training and validation sets. Functional analyses revealed that these genes were involved in immune regulation and PI3K/AKT/mTOR signaling. In vitro experiments confirmed that high glucose induced monocyte activation, as evidenced by increased expression of activation markers (CD86) and pro-inflammatory cytokines (IL-8 and TNF-α). High glucose also increased monocyte apoptosis and altered the expression of key genes (ACTG1, REL, and TRIB1) and immune-related genes (CXCL16, TGFBR1, CTLA4, CD48, TMIGD2, and HLA-DPB1). Knockdown of TRIB1 attenuated high glucose-induced monocyte activation, as demonstrated by decreased expression of activation markers and pro-inflammatory cytokines. TRIB1 knockdown also modulated the expression of immune-related genes and PI3K/AKT/mTOR signaling under high-glucose conditions. Conclusions: This study integrates scRNA-seq, bulk RNA-seq, and experimental validation to unravel the immune mechanisms of T1D. Key genes (ACTG1, REL, and TRIB1) and monocytes were identified as crucial players in T1D pathogenesis. The constructed diagnostic model showed high validation efficiency. In vitro experiments confirmed the role of TRIB1 in regulating monocyte activation and immune-related pathways in a high-glucose model. These findings provide novel insights into the immune mechanisms of T1D and potential diagnostic and therapeutic targets.

Multitissue Multiomics Integration Reveals Tissue-Specific Pathways, Gene Networks, and Drug Candidates for Type 1 Diabetes

An integrative single-cell multi-omics profiling of human pancreatic islets identifies T1D associated genes and regulatory signals.

Identification of Key Gene Pathways and Coexpression Networks of Islets in Human Type 2 Diabetes.

Genetic risk converges on regulatory networks mediating early type 2 diabetes

System Network Analysis of Genomics and Transcriptomics Data Identified Type 1 Diabetes-Associated Pathway and Genes.

Identification of Key Genes and Pathways in Peripheral Blood Mononuclear Cells of Type 1 Diabetes Mellitus by Integrated Bioinformatics Analysis

Elucidate multidimensionality of type 1 diabetes mellitus heterogeneity by multifaceted information

Immune mechanisms of type 1 diabetes revealed by single-cell transcriptomics, bulk transcriptomics, and experimental validation

From Pancreatic β-Cell Gene Networks to Novel Therapies for Type 1 Diabetes

Multiomics single-cell analysis of human pancreatic islets reveals novel cellular states in health and type 1 diabetes

Novel Protein Biomarkers and Therapeutic Targets for Type 1 Diabetes and Its Complications: Insights from Summary-Data-Based Mendelian Randomization and Colocalization Analysis

Parallel Multi-Omics in High-Risk Subjects for the Identification of Integrated Biomarker Signatures of Type 1 Diabetes

Multi-omics characterization of type 2 diabetes associated genetic variation.

Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes

Predicting Cell-Type Specific Disease Genes of Diabetes with the Biological Network

Elucidating the Epigenetic Landscape of Type 2 Diabetes: A Multi-Omics Analysis Revealing Novel CpG Sites and Their Association with Cardiometabolic Traits

Uncovering the gene regulatory network of type 2 diabetes through multi-omic data integration

A multi-ancestry genome-wide association study in type 1 diabetes

Based on systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for diabetes

Fine Mapping of Type 1 Diabetes Susceptibility Loci and Evidence for Colocalization of Causal Variants with Lymphoid Gene Enhancers.

Single-cell Transcriptomics, Web-based Systems Pharmacology and Integrated Transcriptomics Network Analysis Identified Diagnostic Targets and Drug Candidates for Type 2 Diabetes